Enlivex Therapeutics Ltd. Statistics
Share Statistics
Enlivex Therapeutics Ltd. has 21.99M shares outstanding. The number of shares has increased by 15.09% in one year.
| Shares Outstanding | 21.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 2.56% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.27M |
| Failed to Deliver (FTD) Shares | 2.48K |
| FTD / Avg. Volume | 1.02% |
Short Selling Information
The latest short interest is 160.14K, so 0.75% of the outstanding shares have been sold short.
| Short Interest | 160.14K |
| Short % of Shares Out | 0.75% |
| Short % of Float | 0.85% |
| Short Ratio (days to cover) | 1.23 |
Valuation Ratios
The PE ratio is -1.73 and the forward PE ratio is -2.06.
| PE Ratio | -1.73 |
| Forward PE | -2.06 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.67 |
| P/FCF Ratio | -2.11 |
| PEG Ratio | n/a |
Enterprise Valuation
Enlivex Therapeutics Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.57, with a Debt / Equity ratio of 0.
| Current Ratio | 5.57 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -2099.64 |
Financial Efficiency
Return on equity (ROE) is -0.97% and return on capital (ROIC) is -94.47%.
| Return on Equity (ROE) | -0.97% |
| Return on Assets (ROA) | -0.79% |
| Return on Capital (ROIC) | -94.47% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -409.41K |
| Employee Count | 71 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -16.31% in the last 52 weeks. The beta is 1.1, so Enlivex Therapeutics Ltd.'s price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | -16.31% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 244.19K |
Income Statement
In the last 12 months, Enlivex Therapeutics Ltd. had revenue of $0 and earned -$29.07M in profits. Earnings per share was $-1.56.
| Revenue | 0 |
| Gross Profit | -835.00K |
| Operating Income | -29.39M |
| Net Income | -29.07M |
| EBITDA | -28.22M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.56 |
Balance Sheet
The company has $813.00K in cash and $1.03M in debt, giving a net cash position of -$219.00K.
| Cash & Cash Equivalents | 813.00K |
| Total Debt | 1.03M |
| Net Cash | -219.00K |
| Retained Earnings | -112.09M |
| Total Assets | 29.80M |
| Working Capital | 24.32M |
Cash Flow
In the last 12 months, operating cash flow was -$23.52M and capital expenditures -$236.00K, giving a free cash flow of -$23.76M.
| Operating Cash Flow | -23.52M |
| Capital Expenditures | -236.00K |
| Free Cash Flow | -23.76M |
| FCF Per Share | -1.28 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ENLV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -132.2% |
| FCF Yield | -91.57% |
Analyst Forecast
The average price target for ENLV is $13, which is 1001.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 1001.7% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 6, 2019. It was a backward split with a ratio of 1:8.
| Last Split Date | Mar 6, 2019 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -1.56 |
| Piotroski F-Score | 2 |